青年护理人员面对患者死亡心理应激状况的调查研究

目的 了解青年护理人员面对患者死亡的心理应激状况.方法 应用焦虑自评量表(SAS)、抑郁自评量表(SDS)对8所综合性医院急诊、ICU、临终关怀病房等96名青年护理人员(研究组),94名其他病房的青年护理人员(对照组)进行了调查,并进行对比分析.结果 研究组SAS及SDS评分、抑郁和焦虑的发生率均高于对照组,差异有统计学意义(P＜0.05).结论 经常面对患者死亡的青年护理人员,应激障碍发生率高,心理健康水平较低,值得护理管理者密切关注.     

以护理学基础为例浅谈青年专业教师在双语教学中的作用

双语教学在各高校陆续开展，其中师资问题一直是影响双语教学的关键因素。青年专业教师具有良好的英语基础和专业基础，有较高的内在因素和较强的创新能力，有助于高等院校双语教学快速开展。本文就以护理学基础为例对青年教师在双语教学中的作用进行了探讨。     

Multiple Group Confirmatory Factor Analysis of the Young Schema-Questionnaire in a Dutch Clinical versus Non-clinical Population

So far, results on the dimensionality of the Young Schema-Questionnaire (YSQ) were based on exploratory factor analysis. In this study, confirmatory techniques were used to investigate the latent structure of the YSQ and its measurement invariance across a Dutch clinical (n = 172) and non-clinical (n = 162) sample. Data support the 16 factor structure as originally hypothesized by Young (Young, J. E. (1994). Cognitive therapy for personality disorders: A schema-focused approach (Rev. ed.). Sarasota, FL: Professional Resource Press), including Social Undesirability, which did not appear as a separate factor in earlier studies. Furthermore, results suggest factorial similarity across both samples. Best fit was found for a model in which inter-factor correlations and factor loadings were specified as invariant across samples while error variances were allowed to vary. An additional finding was that the YSQ can be split into two parallel parts. Parallel tests represent the same underlying constructs, and share identical psychometric properties, but contain different items. Their utilization could be highly profitable for research and clinical practice.

青壮年甲状腺功能亢进患者的骨密度变化

目的:观察青壮年甲状腺功能亢进患者骨矿物质含量的变化.方法:采用双能X线吸收法测量84例青壮年甲亢患者(甲亢组)和84例与其年龄和性别匹配的正常健康者(对照组)的全身、正位腰椎(L2-4)和左侧股骨近端(包括股骨颈、大粗隆、髋关节)骨矿物质密度(BMD),并同时测量血清游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)水平.结果:在未接受治疗的84例青壮年甲亢患者中,女性有51.7%(30/58)存在骨矿含量异常,其中骨量减少和骨质疏松的发生率分别为36.2%(21/58)和15.5%(9/58);男性有46.2%(12/26)存在骨矿含量异常,其中骨量减少和骨质疏松的发生率分别为15.4%(4/26)和30.8%(8/26).甲亢组的全身、L2-4和左侧股骨近端BMD(除外男性L2～4,P＞0.05)低于对照组(P＜0.01).甲亢组病程、血清FT3、FT4含量与全身、L2～4、左侧股骨近端BMD值呈负相关(除外男性L2～4,P＞0.05).结论:甲亢是青壮年男、女性低骨量和骨质疏松的主要风险因素之一.     

124例青年人大肠癌临床特征

目的：讨青年人大肠癌的临床特征。方法：总结分析复旦大学附属中山医院青年人大肠癌124例患者临床特点、病理特征和生存率。结果：124例青年人大肠癌，平均病程5．5个月，误诊97例，占78．2％，误诊以肠炎、痔疮、痢疾多见。Dukes分期C、D期共95例，占76．6％。病理类型以低分化腺癌、未分化癌、黏液腺癌、印戒细胞癌多见，共71例，占57．3％。124例中81例行根治性手术，根治组5年随访生存率28．4％。结论：青年人大肠癌误诊率高，恶性程度高，预后差。如何早诊和早治是提高生存率的关键。     

Weight loss,adverse events,and loss to follow-up after gastric bypass in young versus older adults: A Scandinavian Obesity Surgery Registry study

Background

Young adults display particularly poor weight loss in behavioral obesity treatment; nonetheless, they have seldom been included in bariatric research.

The blind pushing technique for peripherally inserted central catheter placement through brachial vein puncture

Objective

The objective of this study was to conduct a prospective clinical trial evaluating the technical feasibility and short-term clinical outcome of the blind pushing technique for placement of pretrimmed peripherally inserted central catheters (PICCs) through brachial vein access.

Clinical outcomes in a contemporary series of “young” patients with castration-resistant prostate cancer who were 60 years and younger

BackgroundThe prognosis of younger patients with prostate cancer is unclear, and the very few studies assessing those with metastatic castration-resistant prostate cancer (mCRPC) have mainly involved patients treated with older therapies. The aim of this observational study was to evaluate the clinical outcomes of a contemporary series of docetaxel-treated patients with mCRPC who were 60 years and younger.Patients and methodsWe retrospectively identified 134 patients who were 60 years and younger who were treated with docetaxel in 25 Italian hospitals and recorded their predocetaxel history of prostate cancer, their characteristics at the start of chemotherapy, and their postdocetaxel treatment history and outcomes.ResultsMost of the 134 consecutive patients with mCRPC received the standard 3-week docetaxel schedule; median progression-free survival (PFS) was 7 months, and 90 patients underwent further therapies after progression. The median overall survival (OS) from the start of docetaxel treatment was 21 months, but OS was significantly prolonged by the postprogression treatments, particularly those based on the new agents such as cabazitaxel, abiraterone acetate, or enzalutamide. OS was significantly shorter in the patients with a shorter interval between the diagnosis of prostate cancer and the start of docetaxel treatment; those who received hormonal treatment for a shorter period; those with shorter prostate-specific antigen doubling times; and those with lower hemoglobin levels, a worse performance status, and higher lactate dehydrogenase levels before starting treatment with docetaxel.ConclusionsThe findings of this first study of clinical outcomes in a contemporary series of younger patients with mCRPC showed that their survival is similar to that expected in unselected patients with mCRPC who were of any age.